Skip to Content
Merck
  • Modified periodontal risk assessment score: long-term predictive value of treatment outcomes. A retrospective study.

Modified periodontal risk assessment score: long-term predictive value of treatment outcomes. A retrospective study.

Journal of clinical periodontology (2010-05-29)
Matthieu Leininger, Henri Tenenbaum, Jean-Luc Davideau
ABSTRACT

The aim of this study was to evaluate the long-term clinical predictive value of the periodontal risk assessment diagram surface (PRAS) score and the influence of patient compliance on the treatment outcomes. Thirty subjects suffering from periodontitis were re-examined 6-12 years after the initial diagnosis and periodontal treatments. The baseline PRAS score was calculated from the initial clinical and radiograph records. Patients were then classified into a low-to-moderate (0-20) or a high-risk group (>20). Patients who did not attend any supportive periodontal therapy were classified into a non-compliant group. PRAS and compliance were correlated to the mean tooth loss (TL)/year and the mean variation in the number of periodontal pockets with a probing depth (PPD) >4 mm. TL was 0.11 for the low-to-moderate-risk group and 0.26 for the high-risk group (p<0.05); PPD number reduction was 2.57 and 2.17, respectively, and bleeding on probing reduction was 6.7% and 23.3%, respectively. Comparing the compliance groups, the PPD number reduction was 3.39 in the compliant group and 1.40 in the non-compliant group (p<0.05). This study showed the reliability of PRAS in evaluating long-term TL and patient susceptibility to periodontal disease. Our data confirmed the positive influence of patient compliance on periodontal treatment outcomes.

MATERIALS
Product Number
Brand
Product Description

Spiramycin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Spiramycin
Supelco
Spiramycin from Streptomyces sp., VETRANAL®, analytical standard, mixture of isomers